Fahad Alsaikhan, Saade Abdalkareem Jasim, Ria Margiana, Maria Jade Catalan Opulencia, Ghulam Yasin, Ali Thaeer Hammid, Makhzuna Tahsinovna Nasretdinova, Ahmed B. Mahdi, Bagher Farhood, Razzagh Abedi-Firouzjah, Tannaz jamialahmadi and Amirhosein Sahebkar* Pages 1 - 17 ( 17 )
Introduction: Although cancer treatment with cisplatin is effective, dose-dependent adverse effects such as ototoxicity occurs often, which limits its clinical use. The use of resveratrol may alleviate the cisplatin-induced ototoxic effects. This study is aimed to review the potential otoprotective effects of resveratrol against cisplatin-induced cytotoxicity.
Method: According to the PRISMA guideline, a systematic search was accomplished to identify all relevant scientific papers on “the role of resveratrol against cisplatin-induced ototoxicity” in different electronic databases up to May 2021. Fifty-five articles were screened based on a pre-defined set of inclusion and exclusion criteria. Eight eligible studies were finally included in the current systematic review. The in-vitro findings revealed that cisplatin administration significantly decreased the HEI-OC1 cell viability compared to the untreated cells; however, resveratrol co-treatment (in a dose-dependent manner) could protect HEI-OC1 cells against cisplatin-induced decrease in cell viability.
Results: Furthermore, the in-vivo finding showed a decreased value of DPOAE, and increased values of ABR threshold, ABR-I, ABR-IV, and ABR I-IV interval in cisplatin- treated animals; in contrast, resveratrol co-administration demonstrated an opposite pattern on these parameters.
Conclusion: Thus, it can be mentioned that resveratrol co-treatment alleviates cisplatin- induced ototoxicity. Mechanically, resveratrol exerts its otoprotective effects through various mechanisms such as anti-oxidant, anti-apoptosis, and anti-inflammatory.
Neoplasms, cisplatin, ototoxicity, resveratrol, anti-oxidant, anti-inflammatory.